OPTH and 8BN0 Related Headlines
Go Back- Optimi Health ships psilocybin capsules to Australia in third export
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health ships psilocybin capsules to Australia in third export
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health ships first psilocybin export to UK for phase 2 trial
- Optimi Health exports psilocybin to UK for phase 2 clinical trial
- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Australia expands psychedelic therapy access with updated prescriber rules
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
OPTH and 8BN0 Related Press Releases
Go Back- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
- Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
- Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
- Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
- Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
